OPEN END TURBO BEAR OPTIONSSCHEIN - MODERNA | Market Closed - Bid/Ask 03:40:05 2024-07-12 pm EDT | After market 03:59:57 pm | |||
| 2.67 EUR | +5.95% |
|
2.685 | +0.56% |
| Current month | -14.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 2.67 | +5.95% |
| 24-07-11 | 2.52 | -17.38% |
| 24-07-10 | 3.05 | -3.79% |
| 24-07-09 | 3.17 | 0.00% |
| 24-07-08 | 3.17 | +6.73% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 03:40 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HD6CSJ |
| ISIN | DE000HD6CSJ3 |
| Date issued | 2024-06-17 |
| Strike | 150.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.22 € |
|---|---|
| Lowest since issue | 0.97 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.8
USD
Average target price
145.9
USD
Spread / Average Target
+18.79%
- Stock Market
- Certificates
- Certificat
